The market for biopharmaceutical company initial public offerings and follow-on public offerings has become more friendly this year, but some firms still are circumventing the public offering route an
Ionis Pharmaceuticals Inc. has been in it for the long haul, developing antisense drugs for more than 25 years. But now partnered and independently-owned drugs are in late-stage development and the
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions leading up to the J.P. Morgan Healthcare C
The table records clinical developments using data from Informa Pharma Intelligence’s Biomedtracker. It lists drugs for which an important event was recorded between October 21 and October 27, 2016, d